We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current KSPHF market cap is 1.23B. The company's latest EPS is JPY 226.3178 and P/E is 0.11.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 63.23B | 69.04B | 65.38B | 67.49B | 75.58B |
| Operating Income | 1.86B | 1.51B | -1.4B | -1.13B | 4.02B |
| Net Income | 2.82B | 5.29B | 12.92B | 10.53B | 11.16B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 231.79B | 268.86B | 238.09B | 221.2B | 260.93B |
| Total Liabilities | 38.82B | 48.91B | 35.91B | 26.39B | 39.79B |
| Total Equity | 192.97B | 219.95B | 202.18B | 194.82B | 221.14B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 13.93B | -2.54B | 1.53B | -6.68B | -1.68B |
| Investing | 491M | -9.33B | 10.78B | 6B | 8.69B |
| Financing | -4.42B | -4B | -2.75B | -3.42B | -10.01B |
| Market Cap | 1.23B |
| Price to Earnings Ratio | 0.11 |
| Price to Sales Ratio | 0.02 |
| Price to Cash Ratio | 0.05 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | 27,858.60% |
| Shares Outstanding | 49.31M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 19.67% |
| 52 Week High | 25.00 |
| 52 Week Low | 19.322 |
| Spread (Intraday) | 4.75 (18.29%) |
| Company Name | Kissei Pharmaceuticals Company Ltd (PK) |
| Address |
19-48 yoshino matsumoto, nagano 399-8710 |
| Website | https://www.kissei.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
